JW THERAP-B (02126) rose more than 10%, gaining 9.77% to HKD 3.82 by the time of writing, with a turnover of HKD 4.63 million. Reports indicate that the company's CAR-T cell therapy, Relmacabtagene autoleucel injection, is making progress in negotiations for inclusion in commercial health insurance innovation drug lists. If successful, this would reduce treatment costs for patients and expand access.

Approved as China's first domestically developed Class 1 CAR-T therapy, the drug is priced at RMB 1.29 million per dose. On October 30, JW THERAP-B announced a supplemental strategic collaboration agreement with Regeneron Pharmaceuticals, marking a significant upgrade in their long-term partnership. The deal also initiates a new phase in TCR-T cell therapy and platform technology innovation.

Under the agreement, JW THERAP-B could receive up to USD 50 million in payments, including milestones for MAGE-A4 product development, regulatory approvals for manufacturing processes, option exercise fees, and lentiviral vector production milestones.